397 related articles for article (PubMed ID: 30115750)
21. Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
Çağlayan ES
Cell Biol Int; 2016 Dec; 40(12):1256-1270. PubMed ID: 27743462
[TBL] [Abstract][Full Text] [Related]
22. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
[TBL] [Abstract][Full Text] [Related]
23. QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors.
Koo KA; Kim ND; Chon YS; Jung MS; Lee BJ; Kim JH; Song WJ
Bioorg Med Chem Lett; 2009 Apr; 19(8):2324-8. PubMed ID: 19282176
[TBL] [Abstract][Full Text] [Related]
24. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
25. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
Wegiel J; Dowjat K; Kaczmarski W; Kuchna I; Nowicki K; Frackowiak J; Mazur Kolecka B; Wegiel J; Silverman WP; Reisberg B; Deleon M; Wisniewski T; Gong CX; Liu F; Adayev T; Chen-Hwang MC; Hwang YW
Acta Neuropathol; 2008 Oct; 116(4):391-407. PubMed ID: 18696092
[TBL] [Abstract][Full Text] [Related]
26. Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.
García-Cerro S; Vidal V; Lantigua S; Berciano MT; Lafarga M; Ramos-Cabrer P; Padro D; Rueda N; Martínez-Cué C
Neurobiol Dis; 2018 Feb; 110():206-217. PubMed ID: 29221819
[TBL] [Abstract][Full Text] [Related]
27. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
[TBL] [Abstract][Full Text] [Related]
28. Gene dosage-dependent association of DYRK1A with the cytoskeleton in the brain and lymphocytes of down syndrome patients.
Dowjat K; Adayev T; Kaczmarski W; Wegiel J; Hwang YW
J Neuropathol Exp Neurol; 2012 Dec; 71(12):1100-12. PubMed ID: 23147510
[TBL] [Abstract][Full Text] [Related]
29. Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations.
Toiber D; Azkona G; Ben-Ari S; Torán N; Soreq H; Dierssen M
Neurobiol Dis; 2010 Oct; 40(1):348-59. PubMed ID: 20600907
[TBL] [Abstract][Full Text] [Related]
30. Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
Blazek JD; Abeysekera I; Li J; Roper RJ
Hum Mol Genet; 2015 Oct; 24(20):5687-96. PubMed ID: 26206885
[TBL] [Abstract][Full Text] [Related]
31. Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome.
Laguna A; Barallobre MJ; Marchena MÁ; Mateus C; Ramírez E; Martínez-Cue C; Delabar JM; Castelo-Branco M; de la Villa P; Arbonés ML
Hum Mol Genet; 2013 Jul; 22(14):2775-84. PubMed ID: 23512985
[TBL] [Abstract][Full Text] [Related]
32. Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
Stringer M; Abeysekera I; Dria KJ; Roper RJ; Goodlett CR
Pharmacol Biochem Behav; 2015 Nov; 138():70-9. PubMed ID: 26363314
[TBL] [Abstract][Full Text] [Related]
33. Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction.
Martínez de Lagrán M; Altafaj X; Gallego X; Martí E; Estivill X; Sahún I; Fillat C; Dierssen M
Neurobiol Dis; 2004 Feb; 15(1):132-42. PubMed ID: 14751778
[TBL] [Abstract][Full Text] [Related]
34. DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives.
Neumann F; Gourdain S; Albac C; Dekker AD; Bui LC; Dairou J; Schmitz-Afonso I; Hue N; Rodrigues-Lima F; Delabar JM; Potier MC; Le Caër JP; Touboul D; Delatour B; Cariou K; Dodd RH
Sci Rep; 2018 Feb; 8(1):2859. PubMed ID: 29434250
[TBL] [Abstract][Full Text] [Related]
35. Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.
Burgy G; Tahtouh T; Durieu E; Foll-Josselin B; Limanton E; Meijer L; Carreaux F; Bazureau JP
Eur J Med Chem; 2013 Apr; 62():728-37. PubMed ID: 23454515
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Smith B; Medda F; Gokhale V; Dunckley T; Hulme C
ACS Chem Neurosci; 2012 Nov; 3(11):857-72. PubMed ID: 23173067
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues.
London J; Rouch C; Bui LC; Assayag E; Souchet B; Daubigney F; Medjaoui H; Luquet S; Magnan C; Delabar JM; Dairou J; Janel N
Mol Neurobiol; 2018 May; 55(5):3822-3831. PubMed ID: 28540658
[TBL] [Abstract][Full Text] [Related]
38. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
[TBL] [Abstract][Full Text] [Related]
39. DYRK1A BAC transgenic mouse: a new model of thyroid dysgenesis in Down syndrome.
Kariyawasam D; Rachdi L; Carré A; Martin M; Houlier M; Janel N; Delabar JM; Scharfmann R; Polak M
Endocrinology; 2015 Mar; 156(3):1171-80. PubMed ID: 25490145
[TBL] [Abstract][Full Text] [Related]
40. DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
Pathak A; Rohilla A; Gupta T; Akhtar MJ; Haider MR; Sharma K; Haider K; Yar MS
Eur J Med Chem; 2018 Oct; 158():559-592. PubMed ID: 30243157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
